Format

Send to

Choose Destination
Neurosurg Clin N Am. 2018 Jan;29(1):185-193. doi: 10.1016/j.nec.2017.09.006.

Future Directions and New Technologies for the Management of Degenerative Cervical Myelopathy.

Author information

1
Department of Neurosurgery, Toronto Western Hospital, University Health Network, 399 Bathurst Street 4WW-449, Toronto, Ontario M5T 258, Canada. Electronic address: mario.ganau@alumni.harvard.edu.
2
Department of Neurosurgery, Ronald Reagan UCLA Medical Center, 1250 16th Street, Santa Monica, CA 90404, USA.
3
Department of Neurological Surgery, Aichi Medical University, 480-1195 Aichi Prefecture, Aichi, Japan.
4
Department of Neurosurgery, Toronto Western Hospital, University Health Network, 399 Bathurst Street 4WW-449, Toronto, Ontario M5T 258, Canada.

Abstract

The diagnosis and treatment of degenerative cervical myelopathy (DCM) has been evolving over the past 5 decades as a result of collaborations between clinicians and scientists. The most recent trends in basic and clinical research include advances in imaging, clinical diagnostic tools, molecular genetics, surgical techniques, and reparative/regenerative strategies. Spine surgeons are witnessing a fast-paced evolution, which is reshaping the management strategies available for an aging population that suffers increasingly from this degenerative condition.

KEYWORDS:

Biomaterials; Biomedical engineering; Degenerative cervical myelopathy; Nanotechnology; Neuroprotective drugs; Osteobiologics; Regenerative strategies; Spinal implants

PMID:
29173432
DOI:
10.1016/j.nec.2017.09.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center